Background: The 2015 American Thyroid Association (ATA) guidelines have been proposed to aid in the management of thyroid nodules by determining whether fine needle aspiration is indicated.
T hyroid nodules are common and increasingly discovered with the use of imaging, particularly ultrasound. Ultrasound can detect incidental nodules in #68% of adults, with a higher prevalence found in older adults and women (1, 2) . The evaluation of a thyroid nodule often includes an assessment for malignant potential, which typically includes ultrasound characterization and fine needle aspiration (FNA). Unfortunately, the sonographic appearance of these nodules varies, and no single imaging feature is predictive of malignancy. Thus, risk stratification systems such as the 2015 American Thyroid Association (ATA) guidelines (3) and the American College of Radiology Thyroid Imaging Reporting and Data System (4) have been designed and revised to help physicians treat patients with thyroid nodules.
However, risk stratification is complicated because detection of thyroid cancer has been linked to substantial harm related to the overdiagnosis and overtreatment of low-risk disease. Imaging-based classification systems do not clearly differentiate higher-risk cancers from lower-risk cancers (3, 4) ; rather, they are designed to assess the risk of a nodule being malignant. In those with a reasonable risk of malignancy, FNA is usually recommended, and the histology from that sampling can lead to downstream consequences that may be harmful to the patient (e.g., anxiety, unneeded thyroidectomy, and its associated morbidities). In light of recent evidence challenging routine use of thyroid ultrasound, determining whether imaging-based risk stratification is effective for the detection of clinically significant disease is important. Our purpose was to determine whether the 2015 ATA guidelines effectively stratify thyroid nodules and reduce unnecessary interventions.
Materials and Methods
With institutional review board approval and in compliance with the Health Insurance Portability and Accountability Act, pertinent imaging studies and medical records of the patients in this study were accessed. Participant informed consent was waived by the institutional review board because of the retrospective nature of this investigation.
Subjects
All subjects undergoing first-time FNA of a thyroid nodule in the radiology department at our institution between October 2009 and February 2016 were identified via the electronic medical record system and Department of Radiology records. From this group, 28 patients had undergone repeat procedural visits for FNA of a thyroid nodule, and thus only the most recent procedure was included. For patients who underwent FNA of several nodules in one procedural visit, only the first nodule sampled was included in the data. There were no other exclusion criteria. The final study population consisted of 1947 thyroid nodules in 1947 subjects.
Subjects underwent an ultrasound-guided FNA performed by a member of our cross-sectional interventional service. Before the aspiration procedure, subjects underwent a diagnostic thyroid ultrasound to evaluate the targeted nodules. The diagnostic thyroid ultrasound and FNA were performed with electronically focused linear transducers ranging in frequency from 6 to 15 mHz (GE Logiq 700; GE Medical Systems, Milwaukee, WI; and ATL 3000 and 5000; Advanced Technology Laboratories, Bothell, WA). Aspirations were performed with a series of 25-gauge needles and free-hand technique under direct sonographic visualization. The needle was inserted into the targeted nodules, and aspirations were performed with the capillary method. Varying areas of the nodule were sampled in each pass. A minimum of six passes were performed unless a cytopathologist was present. In these latter cases, cellular adequacy was determined by the cytopathologist, and sampling was stopped if cellular adequacy was obtained. The maximum number of passes was 12.
Image review
One radiologist, with 9 years' experience, was blinded to the cytology results. This radiologist retrospectively reviewed the diagnostic thyroid ultrasound images on a picture archiving and communication workstation, determined whether each nodule had microcalcifications, assigned each nodule one of 14 morphologic descriptors according to the 2015 ATA guidelines (3), and placed each nodule into one of five 2015 ATA categories of risk (ATA-1, ,1% risk of malignancy; ATA-2, ,3% risk; ATA-3, 5% to 10% risk; ATA-4, 10% to 20% risk, ATA-5, .70% to 90% risk). Cysts were placed in ATA-1. Nodules that were interpreted to be spongiform or partially cystic were placed in ATA-2. Nodules that appeared hyperechoic solid with a regular margin, isoechoic with a regular margin, or partially cystic with an eccentric solid area or areas were categorized as ATA-3. Nodules that were hypoechoic solid with a regular margin were placed into ATA-4. Nodules that were hypoechoic with an irregular margin with or without microcalcifications, hypoechoic taller than wide, hypoechoic with an irregular margin and extrathyroidal extension, hypoechoic with interrupted rim calcification with soft tissue extension, or irregular margins with suspicious ipsilateral lymph nodes were placed into ATA-5. Nodule echogenicity, margins, shape, cystic nature, and presence of microcalcifications were assessed according to 2015 ATA guidelines (3) .
A subset of 180 nodules from nine image groups (listed below) was then derived from the entire data set to be used for calculating interrater agreement. This subset included all subclassifications of ATA risk that had $20 nodules represented as classified by the initial reader. For subclassifications with .20 eligible nodules, a set of 20 was randomly selected from that subclassification for inclusion via a random number generator This subset was reviewed by four additional radiologists (with 2 to 30 years of experience) who were blinded to cytology results. These readers retrospectively reviewed the diagnostic thyroid ultrasound images on a picture archiving and communication workstation and determined whether each nodule had microcalcifications, assigned each nodule one of 14 morphologic descriptors according to the 2015 ATA guidelines (3), and placed each nodule into one of five 2015 ATA categories of risk (3).
Cytopathologic reference standard
All thyroid FNAs were interpreted according to the Bethesda system (5) as recommended by the 2015 ATA guidelines (3). The Bethesda system (5) for reporting thyroid cytology is based on the 2007 National Cancer Institute State of Science Conference and provides six diagnostic categories that indicate the risk of cancer. These categories and their risk of malignancy are nondiagnostic, 1% to 4%; benign, 0% to 3%; atypia of undetermined significance,~5% to 15%; suspicious for follicular neoplasm, 15% to 30%; suspicious for malignancy, 60% to 75%; and malignancy 97% to 99%.
For subjects whose initial FNA results were inconclusive (i.e., nondiagnostic, atypia or follicular lesion of undetermined significance, or suspicious for neoplasm), we reviewed the electronic medical record to determine whether a subsequent targeted FNA or surgery was performed to enable a more definitive diagnosis within a year of the initial FNA. In such cases, that final diagnosis was recorded. In cases where no definitive diagnosis was obtained, the initial cytopathology was considered the final result.
Data analysis
Data were summarized with descriptive statistics. The likelihood of thyroid cancer was compared across different demographic groups with a x 2 test for categorical variables and Student t test for continuous variables. The positive predictive value (PPV) of each ATA category was calculated with respect to cancer, cancer or atypia, and any nonpapillary cancer. Final cytology was used to determine the incidence of any nonpapillary cancer. The relationship between ATA category and risk of either any cancer or atypia or any nonpapillary cancer was assessed with Pearson correlation. Numbers needed to sample were calculated for each ATA category.
Interrater agreement for ATA score was assessed with singlemeasure two-way random-effects intraclass correlation coefficients (ICCs). Interrater agreement for the presence of microcalcifications was assessed with k statistics (6). The 95% CIs were calculated. Levels of agreement for ICC were assessed as ,0.40 (poor), 0.40 to 0.59 (fair), 0.60 to 0.74 (good), and 0.75 to 1.00 (excellent). Levels of agreement for k were assessed as 0.00 to 0.20 (slight), 0.21 to 0.40 (fair), 0.41 to 0.60 (moderate), 0.61 to 0.80 (substantial), and 0.81 to 1.00 (almost perfect).
Results
Our study population consisted of 1472 women and 475 men with a mean age of 56 years (range, 26 to 86 years). All subjects remained stable throughout the procedure and were discharged the same day. There were no serious complications.
The mean thyroid nodule diameter was 1. Table 1) .
The PPV for cancer strongly correlated with ATA category, but the PPV for greater ATA scores was less than is stated in the 2015 ATA guidelines (3): ATA-1, 0% (0/14); ATA-2, 2% (4/249); ATA-3, 5% (36/733); ATA-4, 12% (104/850); and ATA-5, 28% (28/101). The PPV for cancer or atypia was also strongly correlated with ATA category, but the PPV for greater ATA scores was also less than is stated in the 2015 ATA guidelines (3) Nodules with an initial cytology result of nondiagnostic (n = 314) were found to be malignant in only Denominators for percentages are the total number of subjects in each row.
2% (5/314) on follow-up, including three nonmicroscopic papillary cancers and two nodules suspicious for follicular cancer (Table 3) . Nodules initially considered suspicious for malignancy had a high likelihood of a final malignant diagnosis on follow-up, ranging from 49% (18/43) for nodules originally considered suspicious for follicular neoplasm to 84% (26/31) for nodules originally considered suspicious for malignancy ( Table 3 ). The histologic finding of microscopic papillary thyroid carcinoma (n = 12) was identified incidentally in the setting of a benign hyperplasia and was not classified as papillary carcinoma or malignancy. The overall interrater agreement for ATA score across all five readers was fair (ICC, 0.460; 95% CI, 0.391-0.533), with pairwise agreement ranging from 0.366-0.606 (ICC). Pairwise interrater agreement for presence of microcalcifications was slight to fair (pairwise k range 0.029-0.400) ( Table 4) .
Discussion
In the United States and many other countries, the incidence of thyroid cancer has increased steadily. In the past decade, the incidence of this cancer has increased on average by 3.8% each year in the United States (7) (8) (9) . If these trends continue, thyroid cancer may move from the 11th most common cancer in the United States to the 4th most common cancer by 2030 (7, 8) . This increased incidence is caused by increased diagnosis of occult cancers and subclinical lesions through a number of pathways, including thyroidectomy for benign disease and diagnostic imaging such as CT and ultrasound (8) (9) (10) (11) . Nearly all newly diagnosed thyroid cancers are differentiated slow-growing papillary cancers in nodules #1 cm in size. Detection of aggressive disease has remained unchanged, as has thyroid cancer mortality (7) (8) (9) . however, the number of thyroidectomies continues to increase (9) .
As an example, the South Korean government in 1999 began a national screening program that allowed inexpensive ultrasound imaging of the neck for thyroid cancer. This program resulted in a 15-fold increase in the detection of thyroid cancer, which surpassed the detection of breast cancer and other common malignancies. Nearly all patients were treated with either radical (67%) or subtotal thyroidectomy (33%). Insurance claim analysis of patients who underwent thyroid surgery in this region revealed complications such as hypoparathyroidism (11%), vocal cord paralysis (2%), and potentially lifelong thyroid replacement therapy (12) . As a result of such data, the US Preventive Services Task Force has recommended against screening for thyroid cancer in asymptomatic adults (13) .
In the most recent version of the ATA guidelines (2015), the ATA stresses minimizing harm from the overtreatment of low-risk patients while providing appropriate treatment of those at higher risk (3). However, it is unclear whether the ATA risk stratification system was optimized for detection of any cancer (including indolent cancers for which early detection is unlikely to benefit the patient) or for higher-risk cancer more specifically, especially when the risk estimates are greatly increased with higher ATA categories. Our data demonstrate that the ATA system does effectively stratify risk of thyroid cancer but with the indirect harm of detecting an order of magnitude more low-risk disease (7) . Based on our data, with the ATA scores used as a threshold to stratify the need for thyroid nodule sampling, the number needed to sample or aspirate to detect cancer was 62 (ATA-2), 20 (ATA-3), 8 (ATA-4), and 4 (ATA-5), which was higher than for detecting either cancer or atypia: 17 (ATA-2), 6 (ATA-3), 4 (ATA-4), and 3 (ATA-5).
The PPVs we observed for ATA-3, ATA-4, and ATA-5 observations were less than or in the lower range reported in the ATA guidelines. For example, the stated risk of malignancy in an ATA-3 nodule is reported to be 5% to 10% (3), and we observed a rate of 5%. The stated risk in an ATA-4 nodule is 10% to 20%, and we observed a rate of 12%. The stated risk in an ATA-5 nodule is .70% to 90%, and we observed a rate of 28%, which is far less than what is predicted by the ATA classification. This implies that the ATA guidelines are overly optimistic regarding the cancer detection rates for higherrisk ATA nodules. According to the ATA guidelines, highly suspicious nodules detected on ultrasound should undergo repeat imaging and FNA within 12 months; however, in our study group, repeat FNA may not be practical with the low PPV associated with ATA-5 nodules. Once a nodule is detected, active surveillance may be a promising strategy in patients with both lowrisk disease and high-risk disease categories based on the actual observed rate of malignancy found in this study. Active surveillance has been evaluated in prospective trials by Ito et al. (14, 15) . These investigators studied a cohort of patients who underwent immediate surgery after the diagnosis of papillary thyroid cancer, whereas another cohort underwent surveillance. After 4 to 6 years of follow-up, there was no difference in mortality rates between the two groups; no deaths occurred, and no subjects on active surveillance developed metastatic disease or locoregional spread. Such trials highlight the need for improved management strategies in patients with thyroid nodules with a low risk of malignancy and those with suspected or known thyroid cancer. These trials also demonstrate the need for more rigorous classifications to guide management. Our study has limitations. Although we included a large number of consecutive subjects undergoing firsttime FNA of thyroid nodules over a long period of time, because of the retrospective design it is possible that selection biases at our institution could affect the PPVs of the ATA categories we analyzed. Although 1947 nodules is a large sample size, it may not reflect the higher-risk populations seen by endocrinologists, where the prevalence of thyroid malignancy may be higher. It is hypothesized that the ATA classification may be more appropriate in this setting. Another limitation is that the primary ATA classification was assigned by one experienced expert in ultrasound who is familiar with the ATA guidelines. That individual's performance is confirmed by the strong relationship between assigned ATA scores and risk of malignancy, but it is possible the results would have been different if other raters had evaluated the entire group of nodules. We attempted to account for this limitation by measuring interrater agreement across five readers in a subset of 180 nodules. We found that the reliability or agreement among the readers was only fair. Therefore, on a per-patient basis, the ATA scores are likely to vary between different readers. The lack of reproducibility of results in our practice probably reflects the lack of reproducibility in multiple practices throughout the country. Although this is an acknowledged limitation, this study may be a more accurate representation of applying the criteria across a variety of practitioners interpreting thyroid ultrasound. Another limitation is that a majority of nodules lacked histological confirmation of the initial FNA, indicating that a definitive diagnosis was unknown. Within this group, 226 subjects (12%) had both an indeterminate initial cytology and an indeterminate final diagnosis. This limitation is similar to more recent publications that note that varying rates of malignancy have been reported in indeterminate nodules and thus demonstrates the need for a large series evaluating this group (16) . Fortunately, the Bethesda system for reporting thyroid cytopathology has recently been revised, incorporating new data and developments in the management of thyroid nodules. The 2017 system has substantiated, strengthened, and improved the estimation of risk of malignancy associated with the six original categories: nondiagnostic, 5% to 10%; benign, 0% to 3%; atypia of undetermined significance or follicular lesion of undetermined significance, 10% to 30%; follicular neoplasm or suspicious for a follicular neoplasm, 25% to 40%; suspicious for malignancy, 50% to 75%; and malignant, 97% to 99% (17) . These risks are similar to those reported with the previous Bethesda system. Finally, the impact of molecular diagnostics was not included in this study because this was not the primary objective of our study. Molecular diagnostics is an important component in today's current practice. However its impact is still in question. Dedhia et al. (18) reported that in their practice, molecular diagnostics had limited effect in preventing thyroidectomies in patients found to have indeterminate nodules.
In conclusion, the 2015 ATA guidelines effectively stratify risk for cancer, but the predictive value for detecting thyroid cancer is low, particularly in nodules considered to have higher risk of malignancy. Detection of these cancers is thus accompanied by the harm of detecting an order of magnitude more low-risk disease and can result in the overtreatment of a large number of patients. Improved methods of risk stratification are needed to identify those who would benefit most from immediate FNA and ultimately surgery. In addition, the effectiveness of the guidelines may be hampered by varied interpretations of the sonographic classification of thyroid nodules.
